iData Insights

Women Infertility - Pipeline Review, H2 2015 Is Released

Press Release   •   Feb 01, 2016 15:53 IST

This report provides comprehensive information on the therapeutic development for Women Infertility, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Women Infertility and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Women Infertility

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Women Infertility and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Women Infertility products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Women Infertility pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Women Infertility - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Women Infertility pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC

To Get Sample Copy of Report visit

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Women Infertility Overview 10

Therapeutics Development 11

Pipeline Products for Women Infertility - Overview 11

Pipeline Products for Women Infertility - Comparative Analysis 12

Women Infertility - Therapeutics under Development by Companies 13

Women Infertility - Therapeutics under Investigation by Universities/Institutes 17

Women Infertility - Pipeline Products Glance 18

Late Stage Products 18

Clinical Stage Products 19

Early Stage Products 20

Unknown Stage Products 21

Women Infertility - Products under Development by Companies 22

Women Infertility - Products under Investigation by Universities/Institutes 27

Women Infertility - Companies Involved in Therapeutics Development 28

AbbVie Inc. 28

Addex Therapeutics Ltd 29

Allergan Plc 30

AlphaMab Co., Ltd 31

APAvadis Biotechnologies Srl 32

ASKA Pharmaceutical Co., Ltd. 33

Astellas Pharma Inc. 34

Bayer AG 35


Dong-A Socio Group 37

Dongkook Pharmaceutical Co., Ltd. 38

ElexoPharm GmbH 39

EndoCeutics, Inc. 40

Enteris BioPharma, Inc. 41

Euroscreen S.A. 42

Evotec AG 43

Ferring International Center S.A. 44

Finox AG 45

Forendo Pharma Limited 46

GlaxoSmithKline Plc 47

Glycotope GmbH 48

Kissei Pharmaceutical Co., Ltd. 49

Lipicard Technologies Limited 50

Merrion Pharmaceuticals Plc 51

Nippon Shinyaku Co., Ltd. 52

Nora Therapeutics, Inc. 53

ObsEva SA 54

Orphagen Pharmaceuticals, Inc. 55

Pantec Biosolutions AG 56

PharmaEssentia Corporation 57

Philogen S.p.A. 58

Reliance Life Sciences Pvt. Ltd. 59

Repros Therapeutics Inc. 60

SK Chemicals Co., Ltd. 61

Takeda Pharmaceutical Company Limited 62

TocopheRx, Inc. 63

Trophogen, Inc. 64

ValiRx Plc 65

Viteava Pharmaceuticals, Inc. 66

Zydus Cadila Healthcare Limited 67

Women Infertility - Therapeutics Assessment 68

Assessment by Monotherapy Products 68

Assessment by Combination Products 69

Assessment by Target 70

Assessment by Mechanism of Action 73

Assessment by Route of Administration 76

Assessment by Molecule Type 78

Drug Profiles 80

(anastrozole + levonorgestrel) - Drug Profile 80

acolbifene hydrochloride + prasterone + GnRH agonist - Drug Profile 81

AKP-501 - Drug Profile 82

ASP-1707 - Drug Profile 83

barusiban - Drug Profile 84

BAY-1128688 - Drug Profile 85

bentamapimod - Drug Profile 86

Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile 87

Biosimilar 5 for Infertility - Drug Profile 88

Biosimilar 6 for Infertility - Drug Profile 89

Biosimilar 7 for Infertility and Oncology - Drug Profile 90

choriogonadotropin alfa - Drug Profile 91

DKF-301 - Drug Profile 92

DKF-304 - Drug Profile 93

Drug to Inhibit C-Jun for Endometriosis - Drug Profile 94

Drugs for Endometriosis - Drug Profile 95

Drugs for Endometriosis and Uterine Fibroids - Drug Profile 96

elagolix sodium - Drug Profile 97

epelsiban besylate - Drug Profile 99

ESN-364 - Drug Profile 101

EVE-104 - Drug Profile 103

FE-999310 - Drug Profile 104

follitropin alfa - Drug Profile 105

follitropin alfa - Drug Profile 107

follitropin alfa - Drug Profile 108

follitropin alfa (recombinant) - Drug Profile 109

follitropin delta - Drug Profile 110

FP-5677 - Drug Profile 111

FSH-GEX - Drug Profile 112

kisspeptin-54 - Drug Profile 114

KLH-2109 - Drug Profile 115

KN-015 - Drug Profile 116

leuprolide acetate - Drug Profile 117

LM-001 - Drug Profile 118

LM-002 - Drug Profile 119

LT-6121 - Drug Profile 120

menotropins - Drug Profile 121

MER-104 - Drug Profile 122

MIA-602 - Drug Profile 124

Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile 126

Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 127

NCE-403 - Drug Profile 128

NS-580 - Drug Profile 129

NT-100 - Drug Profile 130

OBE-001 - Drug Profile 131

PEG-FSH - Drug Profile 132

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.